Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.
Identification of biomarkers and target drugs for melanoma: a topological and deep learning approach
and BRAF and NRAS mutation status. Samples were stratified into two groups based on pathological diagnosis: melanocytic nevi (n = 23) and melanoma (n = 57). Previous studies often identified several ...
Mutations in other RAS genes also contribute to human cancers, for example, NRAS mutations are common in melanoma, while HRAS mutations frequently occur in head and neck cancers. Amplification and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback